- +62 21 29189160 (ext. 201912)
- manajer.riset.fkui1@gmail.com
- Senin-Jum'at 8.00 s/d 16.00 WIB
Publikasi Scopus 2024 per tanggal 31 Mei 2024 (409 artikel)
Publikasi Scopus 2024 per tanggal 31 Mei 2024 (409 artikel)
Karuniawati, Anis (54886816200); Pasaribu, Ayodhia Pitaloka (57217846705); Lazarus, Gilbert (57214599425); Irawany, Vera (57224445981); Nusantara, Dwi Utomo (57220637156); Sinto, Robert (36099377100); Suwarti (58107161900); Nasution, Maulana Jamil (57296030300); Ferawati (58855102100); Lubis, Muhammad Riza (58854913800); Nurfitri, Eka (58854542900); Mutiara, Mutiara (57580893800); Arifin, Hasanul (56059171300); Hely, Hely (58853980800); Putri, Pramaisshela Arinda D. (58634157900); Pradipta, Arie
Characteristics and clinical outcomes of patients with pre-delta, delta and omicron SARS-CoV-2 infection in Indonesia (2020–2023): a multicentre prospective cohort study
2024
The Lancet Regional Health - Southeast Asia
22
100348
1
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85183650276&doi=10.1016%2fj.lansea.2023.100348&partnerID=40&md5=61a3c078779cc2717e19b019a23785bb
Department of Microbiology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Paediatrics, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia; Yayasan Penguatan Kesehatan Masyarakat Tridarma (YPKMT/THEMP Foundation), Medan, Indonesia; Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Fatmawati General Hospital, Jakarta, Indonesia; Pasar Minggu Hospital, Jakarta, Indonesia; Division of Tropical and Infectious Diseases, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Pelni Hospital, Jakarta, Indonesia; Murni Teguh Memorial Hospital, Medan, Indonesia; Bunda Thamrin Hospital, Medan, Indonesia; Genomik Solidaritas Indonesia Lab, Jakarta, Indonesia; Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Medical Physiology and Biophysics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Karitas Hospital, Sumba Barat Daya, East Nusa Tenggara, Indonesia; Pratama Reda Bolo Hospital, Sumba Barat Daya, East Nusa Tenggara, Indonesia; Sumba Foundation, Sumba Barat, East Nusa Tenggara, Indonesia; Eijkman Molecular Biology Research Center, National Research and Innovation Agency, Jakarta, Indonesia; Faculty of Medicine, Universitas Nusa Cendana, Kupang, Indonesia; Prof. Dr. W.Z. Johannes Hospital, Kupang, Indonesia; Monash University Indonesia, Tangerang Selatan, Indonesia; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
Background: Limited data exist from southeast Asia on the impact of SARS-CoV-2 variants and inactivated vaccines on disease severity and death among patients hospitalised with COVID-19. Methods: A multicentre hospital-based prospective cohort was enrolled from September 2020 through January 2023, spanning pre-delta, delta, and omicron periods. The participant hospitals were conveniently sampled based on existing collaborations, site willingness and available study resources, and included six urban and two rural general hospitals from East Nusa Tenggara, Jakarta, and North Sumatra provinces. Factors associated with severe disease and day-28 mortality were examined using logistic and Cox regression. Findings: Among 822 participants, the age-adjusted percentage of severe disease was 26.8% (95% CI 22.7–30.9) for pre-delta, 50.1% (44.0–56.2) for delta, and 15.2% (9.7–20.7) for omicron. The odds of severe disease were 64% (18–84%) lower for omicron than delta (p < 0.001). One or more vaccine doses reduced the odds of severe disease by 89% (65–97%) for delta and 98% (91–100%) for omicron. Age-adjusted mortality was 11.9% (8.8–15.0) for pre-delta, 24.4% (18.8–29.9) for delta and 9.6% (5.2–14.0) for omicron. The day-28 cumulative incidence of death was lower for omicron (9.2% [5.6–13.9%]) than delta (28.6% [22.0–35.5%]) (p < 0.001). Severe disease on admission was the predominant prognostic factor for death (aHR34.0 [16.6–69.9] vs mild-or-moderate; p < 0.001). After controlling for disease severity on admission as an intermediate, the risk of death was 48% (32–60%) lower for omicron than delta (p < 0.001); and 51% (38–61%; p < 0.001) lower for vaccinated participants than unvaccinated participants overall, and 56% (37–69%; p < 0.001) for omicron, 46% (−5 to 73%; p = 0.070) for pre-delta (not estimable for delta). Interpretation: Infections by omicron variant resulted in less severe and fatal outcomes than delta in hospitalised patients in Indonesia. However, older, and unvaccinated individuals remained at greater risk of adverse outcomes. Funding: University of Oxford and Wellcome Trust. © 2023
Wellcome Trust, WT; University of Oxford
University of Oxford and Wellcome Trust.
Elsevier Ltd
27723682
Article
#N/A
#N/A
#N/A
© 2024 Riset & Pengabdian Masyarakat. All Rights Reserved.